Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
This partnership has led to a 10% boost in delivery speed
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Subscribe To Our Newsletter & Stay Updated
